UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 14A

PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE

SECURITIES EXCHANGE ACT OF 1934

(Amendment No.     )

 

 

Filed by the Registrant  ☒                             Filed by a Party other than the Registrant  ☐

Check the appropriate box:

 

  Preliminary Proxy Statement
  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
  Definitive Proxy Statement
  Definitive Additional Materials
  Soliciting Material Pursuant to § 240.14a-12

Altimmune, Inc.

(Name of Registrant as Specified In Its Charter)

 

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

  No fee required.
  Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
  (1)  

Title of each class of securities to which transaction applies:

 

     

  (2)  

Aggregate number of securities to which transaction applies:

 

     

  (3)  

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

 

     

  (4)  

Proposed maximum aggregate value of transaction:

 

     

  (5)  

Total fee paid:

 

     

  Fee paid previously with preliminary materials.
  Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
  (1)  

Amount Previously Paid:

 

     

  (2)  

Form, Schedule or Registration Statement No.:

 

     

  (3)  

Filing Party:

 

     

  (4)  

Date Filed:

 

     

 

 

 


*** Exercise Your Right to Vote ***

Important Notice Regarding the Availability of Proxy Materials for the

Shareholder Meeting to Be Held on October 13, 2017

ALTIMMUNE INC.

 

           
     

 

Meeting Information

 

Meeting Type: Annual Meeting

 

For holders as of: August 18, 2017

 

Date: October 13, 2017         Time: 10:00 AM EST

 

Location:   Proskauer Rose LLP

 1001 Pennsylvania Avenue NW

 Washington, D.C. 20004

  
        
     

 

You are receiving this communication because you hold shares in the above named company.

 

This is not a ballot. You cannot use this notice to vote these shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. You may view the proxy materials online at www.proxyvote.com or easily request a paper copy (see reverse side).

 

We encourage you to access and review all of the important information contained in the proxy materials before voting.

  
        
        

LOGO

        
      See the reverse side of this notice to obtain proxy materials and voting instructions.   


 

 

 

 

LOGO

— Before You Vote —

How to Access the Proxy Materials

 

Proxy Materials Available to VIEW or RECEIVE:

 

  
1. Annual Report    2. Notice & Proxy Statement        
How to View Online:   
Have the information that is printed in the box marked by the arrow  LOGO (located on the following page) and visit: www.proxyvote.com.   
How to Request and Receive a PAPER or E-MAIL Copy:   
If you want to receive a paper or e-mail copy of these documents, you must request one. There is NO charge for requesting a copy. Please choose one of the following methods to make your request:   
                                                                       1)  BY INTERNET :           www.proxyvote.com
  
                                                                       2)  BY TELEPHONE :       1-800-579-1639   
                                                                       3)  BY E-MAIL* :                 sendmaterial@proxyvote.com   

 

*   If requesting materials by e-mail, please send a blank e-mail with the information that is printed in the box marked by the arrow   LOGO (located on the following page) in the subject line.

  

 

Requests, instructions and other inquiries sent to this e-mail address will NOT be forwarded to your investment advisor. Please make the request as instructed above on or before October 01, 2017 to facilitate timely delivery.

 

  

— How To Vote —

Please Choose One of The Following Voting Methods

 

 

Vote In Person: If you choose to vote these shares in person at the meeting, you must request a “ legal proxy. ” To do so, please follow the instructions at www.proxyvote.com or request a paper copy of the materials, which will contain the appropriate instructions. Many shareholder meetings have attendance requirements including, but not limited to, the possession of an attendance ticket issued by the entity holding the meeting. Please check the meeting materials for any special requirements for meeting attendance.

  

 

Vote By Internet: To vote now by Internet, go to www.proxyvote.com. Have the information that is printed in the box marked by the arrow   LOGO available and follow the instructions.

  

 

Vote By Mail: You can vote by mail by requesting a paper copy of the materials, which will include a voting instruction form.

 

  
 


 

 

 

 

LOGO

 

Voting items            
The Board of Directors recommends that you
vote FOR the following:
           

 

1.

  

 

Election of Directors

                
  

 

Nominees

                

 

01

  

 

William J. Enright

    

 

        02  David J. Drutz, M.D.

 

 

        03  John M. Gill

    

 

04  Philip L. Hodges

 

 

        05  Mitchel B. Sayare, Ph.D

  
06    Klaus O. Schafer, MD, MPH              07  Derace L. Schaffer M.D.          

 

The Board of Directors recommends you vote FOR the following proposal(s):

           

 

2.

  

 

Vote to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2017.

   

 

7.

  

 

Vote to approve an amendment to our Amended and Restated Certificate of Incorporation, as amended, to permit the Board to fill vacancies on the Board of Directors

  

 

3.

  

 

Hold an advisory vote on the compensation of the Company’s named executive officers as disclosed in the attached Proxy Statement.

   

 

8.

  

 

Vote to approve an amendment to our Amended and Restated Certificate of Incorporation, as amended,to give the Board the flexibility to determine on a case-by-case basis as to whether indemnification should be provided by the Company (other than with respect to officers and directors).

  

 

The Board of Directors recommends you vote 1 YEAR on the following proposal:

         

 

4.

  

 

Hold an advisory vote on the frequency of future advisory votes on the compensation of the Company’s named executive officers.

   

 

9.

  

 

Vote to approve the amendment and restatement of our Amended and Restated Certificate of Incorporation.

  

 

The Board of Directors recommends you vote FOR the following proposal(s):

 

5.   Vote to approve an amendment to our Amended and Restated Certificate of Incorporation, as amended, to include a provision pursuant to which we will be governed by Section 203 of the General Corporation Law of the State of Delaware.

   

 

10.

  

 

Vote, for purposes of complying with Nasdaq Listing Rules 5635(b) and 5635(d), the issuance of shares of our common stock underlying our Series B Convertible Preferred Stock and related Warrants issued by us pursuant to the terms of the Securities Purchase Agreement, dated August 16, 2017,between the Company and the investors named therein.

  

 

6.

  

 

Vote to approve an amendment to our Amended and Restated Certificate of Incorporation, as amended, to include a provision to eliminate the ability of stockholders to act by written consent.

         
         
         
         
         
         
 
Pharmathene, (delisted) (AMEX:PIP)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Pharmathene, (delisted) Charts.
Pharmathene, (delisted) (AMEX:PIP)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Pharmathene, (delisted) Charts.